Longevity gets a state budget in Dubai and a Red Sea flagship, while investors and scientists ask for proof

Dubai has approved a Longevity Authority strategy that targets more than Dh35 billion (about $9.5B) in economic contribution over the next decade. It is a government-backed commitment with a concrete target, which sets it apart from the usual run of clinic announcements.

For advisors, the practical signal is that Dubai is positioning itself as a medical-wellness and longevity destination. Expect new clinics, programs and resort partnerships to follow, though the sources do not yet name specific products or opening dates. Advisors with longevity-minded clients should start tracking Dubai packages and supplier launches now, and ask existing partners how they plan to take part. Treat the figure as a target, not a forecast of bookings.

Miraval Resorts & Spas has opened its first international property, Miraval The Red Sea, on Shura Island in Saudi Arabia. The resort has 180 keys and a 40,000 sq ft Life in Balance spa with 39 treatment rooms. It also offers regional treatments.

That adds a new luxury wellness destination in the Red Sea for advisors to sell, and it extends a US-centred brand into a market where wellness is being built out quickly. One caution: the source is a Robb Report partner (sponsored) piece, so rates, commission terms and program details are not independently confirmed. Check them directly with the resort before pitching it to clients.

MMGY's fall survey puts expected US leisure travel spend at $5,655. Demand is holding up, but travelers are adjusting how they spend. 35% are traveling off-peak, and 64% cite lower cost as a reason for staying domestic.

Spending intent varies by generation: Boomers plan to spend $8,796, against $2,195 for Gen Z. Advisors should expect premium wellness demand to skew toward older, higher-income clients, with value-conscious shoulder-season bookings alongside it. 51% of travelers use AI for planning, so advisors should position their expertise against it.

Coverage this week questions whether the longevity boom has outrun its evidence. Separately, Oura has become the latest US IPO hopeful to delay its listing amid market jitters.

Neither item affects bookings directly. Together they hint at cooler investor appetite for consumer longevity tech, and they raise the reputational stakes for programs that make strong claims. Advisors selling medical-longevity programs should be ready to discuss evidence-based claims and screening rigor with clients. Ask suppliers what they measure and how.